Description
ProductAvailABIlity:InStock(deliverywithin2-3businessdays,noextrachargefordrop-shipping).
Ordering:ToplaceanorderviacreditcardorPOuseAddtoCartbutton(creatinganaccountisnotrequired).
TransfectionReagentforNCI-H358Cells(BronchioalveolarCells,CRL-5807)
- Ananoparticle-basedliposomeformulation
- Transfectionprotocolsprovidedfortransfectionofproteins,DNA,mRNA,siRNA,shRNAandmicroRNA
- TransfectionEnhancerreagentprovidedwiththekit
- Producehigherlevelofrecombinantproteinexpressionwithminimaldisruptionofnormalcellfunction
- Generatephysiologicallyrelevantdatayoucantrust
- EffectiveforplasmidDNA/siRNAco-transfection
- Easy-to-usetransfectionprotocolwithreproducIBLeresults
- Lowcytotoxicity
- DownloadinvitroNCI-H358transfectionprotocol:[PDF]
- Download NCI-H358CRISPR/Cas9transfectionprotocol:[PDF]
- DownloadPowerPointpresentationforNCI-H358transfectionkit:[PPT]
- DevelopedandmanufacturedbyAltogenBiosystems
TransfectionEfficiency:
Reagentexhibitsatleast89%transfectionefficiencyofsiRNAdelivery.TransfectionefficiencywasdeterminedbyqRT-PCR.
TransfectionProtocolandMSDS:
DownloadAltogenBiosystemsNCI_H358TransfectionProtocol:[PDF]
DownloadMSDS:[PDF]
NCI-H358CellLine:
Lungcancerisconsideredtheprimarycauseofcancerdeath,accountingfor14%ofallnewcancerdiagnosesandresponsiblefor1in4cancerfatalities,withthe5-yearsurvivalrateofonly18%,asstatedbytheAmericanCancerSociety.TheNCI-H358epithelialcelllinewasestablishedin1981byA.F.Gazdaretal.frombronchioletissueofapatientwithbronchioalveolarcarcinoma,atypeoflungcancer.Thetumortissuewasremovedpriortothepatientundergoingchemotherapy.TheNCI-H358celllinehasbeenknowntohaveadoublingtimeofroughly38hours.UltrastructuralstudiesdetectedthepresenceofClaracells.Inadditiontobeinganexcellenttransfectionhost,theNCI-H358celllineisrelevantinvitromodelforresearchonmedicaltreatmentsaddressinglungcancer.AltogenBiosystemsoffersnanoparticle-basedtransfectionreagentkitsforthiscellline.
Data:
Figure1.CyclophilinBsilencingefficiencywasdeterminedbyqRT-PCRintheNCI-H358cellstransfectedbyCyclophilinBsiRNAornon-silencingsiRNAcontrolfollowingtherecommendedtransfectionprotocol.CyclophilinmRNAexpressionlevelsweremeasured48hourspost-transfection.18SrRNAlevelswereusedtonormalizetheCyclophilinBdata.Valuesarenormalizedtountreatedsample.Dataarepresentedasmeans±SD(n=6).
Figure2.ProteinexpressionofCyclophilinBinNCI-H358cells.DNAplasmidexpressingCyclophilinBorsiRNAtargetingCyclophilinBweretransfectedintoNCI-H358cellsfollowingAltogenBiosystemstransfectionprotocol.At72hourspost-transfectionthecellswereanalyzedbyWesternBlotforproteinexpressionlevels(normalizedbytotalprotein,10µgoftotalproteinloadedpereachwell).Untreatedcellsusedasanegativecontrol.
NCI-H358TransfectionKit
AltogenBiosystems:
AltogenBiosystemsmanufacturerspreoptimizedtransfectionkitsforcancerresearch.Reagentsandtransfectionprotocolsareoptimizedforindividualcancercelllines.AltogenBiosystemsdevelopedtwotypesofinvivodeliverykitsforanimalresearch:Tissue-targetedreagents(deliveryintoliver,pancreas,andkidneytissues),andinvivobiodistributionreagents(PEG-Liposome,Nanoparticle,Lipid,andPolymer-basedkits).Optimizedtransfectionprotocolsprovideefficientintracellulardeliveryofproteins,DNA,andRNAmoleculesinvitroandinvivo.Readmore abouttransfectiontechnologyatAltogen’sTransfectionResource.
AltogenLabsResearchServices:
AltogenLabsprovidesGLP-compliantcontractresearchstudiesforpre-clinicalresearch,INDapplications,anddrugdevelopment.BIOLOGyCROservices include:Xenograftmodels(30+),developmentofstablecelllines,ELISAassaydevelopment,cell-basedandtissuetargetedRNAistudies,safetypharm/toxassays,andotherstudies(visitAltogenLabs.com).
VolumeOptions:
- 0.5ml(Catalog#6860)
- 1.5ml(Catalog#6861)
- 1.5mlCRISPR(Catalog#2180)
- 8.0ml(Catalog#7069)